*ST长药重大违法将强制退市!逆势四连板谁在炒作?

Core Viewpoint - *ST Changyao faces multiple delisting risks due to significant violations, including administrative penalties and financial misreporting, leading to a suspension of trading and initiation of delisting procedures by the Shenzhen Stock Exchange starting January 26, 2026 [2][5]. Group 1: Regulatory Actions - On January 23, *ST Changyao received an administrative penalty from the China Securities Regulatory Commission (CSRC), which included a warning and a fine of 10 million yuan for false reporting in annual reports from 2021 to 2023 [2]. - The CSRC's investigation into *ST Changyao's financial misconduct was completed in just over two months, reflecting a strong regulatory stance against market irregularities [5]. Group 2: Financial Performance and Risks - The company has reported continuous financial losses, with projected revenues for 2025 estimated between 120 million to 170 million yuan, and net losses expected to be between 350 million to 520 million yuan [9]. - *ST Changyao has indicated that it may have negative net assets by the end of 2025, which could lead to termination of its stock listing under relevant regulations [9]. Group 3: Market Reactions - Despite the delisting risks, *ST Changyao's stock experienced speculative trading, achieving a four-day consecutive limit-up, with the stock price reaching 0.92 yuan per share [8]. - Analysts have warned that the current stock price movements disregard the serious administrative penalties and potential delisting, indicating a high level of investment risk [8].

*ST长药重大违法将强制退市!逆势四连板谁在炒作? - Reportify